U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07554547) titled 'Crizanlizumab Pregnancy Outcomes Intensive Monitoring' on April 21.
Brief Summary: This was a non-interventional study to evaluate pre-specified pregnancy and infant outcomes in women treated with crizanlizumab during pregnancy or within 105 days before the last menstrual period (LMP).
Study Start Date: Nov. 15, 2020
Study Type: OBSERVATIONAL
Condition:
Sickle Cell Disease
Recruitment Status: COMPLETED
Sponsor: Novartis Pharmaceuticals
Published by HT Digital Content Services with permission from Health Daily Digest....